for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AEterna Zentaris Inc. (USA)

AEZS.OQ

Latest Trade

1.01USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.83

 - 

5.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.01
Open
--
Volume
--
3M AVG Volume
2.96
Today's High
--
Today's Low
--
52 Week High
5.56
52 Week Low
0.83
Shares Out (MIL)
19.96
Market Cap (MIL)
17.54
Forward P/E
0.50
Dividend (Yield %)
--

Latest Developments

More

Aeterna Zentaris Announces Appointment Of New President And CEO

Aeterna Zentaris Reports Qtrly Loss Per Share Of $0.01

Aeterna Zentaris Inc Files For Mixed Shelf Of Up To $45 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AEterna Zentaris Inc. (USA)

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Industry

Biotechnology & Drugs

Contact Info

315 Sigma Dr Ste 302D

+1.843.9003223

http://www.aezsinc.com/

Executive Leadership

Carolyn Egbert

Independent Chairman of the Board

Klaus Paulini

President, Chief Executive Officer

Leslie Auld

Chief Financial Officer, Senior Vice President

Richard Sachse

Senior Vice President, Chief Scientific Officer, Chief Medical Officer

Jude P Dinges

Chief Commercial Officer, Senior Vice President

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.410

2017

-1.360

2018

0.250

2019(E)

1.770
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.67
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-62.09
Return on Equity (TTM)
-47.11

Latest News

Latest News

BRIEF-Aeterna Zentaris Reports Qtrly Earnings Per Share $0.87

* AETERNA ZENTARIS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

BRIEF-Aeterna Zentaris Qtrly Loss Per Share $0.03

* AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS

BRIEF-Aeterna Zentaris Appoints James Clavijo As CFO

* AETERNA ZENTARIS APPOINTS JAMES CLAVIJO AS CHIEF FINANCIAL OFFICER

BRIEF-Aeterna Zentaris Provides Update On Previously Disclosed Class Action Lawsuit

* AETERNA ZENTARIS PROVIDES UPDATE ON PREVIOUSLY DISCLOSED CLASS ACTION LAWSUIT

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

BRIEF-Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore

* AETERNA ZENTARIS PROVIDES UPDATE ON LITIGATION AGAINST DAVID DODD AND PHILIP THEODORE

BRIEF-David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris

* DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS

Canada's Aeterna gets FDA approval for growth hormone deficiency test

Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency.

BRIEF-Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency

* AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY

BRIEF-Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer

* AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER

BRIEF-Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA

* AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY

BRIEF-Aeterna Zentaris reports Q3 loss per share of $0.61

* Aeterna Zentaris reports third quarter 2017 financial and operating results

BRIEF-Aeterna Zentaris announces appointment of interim chief financial officer

* Aeterna zentaris announces appointment of interim chief financial officer

BRIEF-Aeterna Zentaris reports Q2 loss per share $0.18

* Aeterna Zentaris reports second quarter 2017 financial and operating results

BRIEF-Aeterna Zentaris engages advisors and provides update to shareholders

* Aeterna Zentaris engages advisors and provides update to shareholders

BRIEF-David Dodd responds to claim filed by Aeterna Zentaris

* David Dodd, former CEO of Aeterna Zentaris, responds to claim filed by Aeterna Zentaris against him & Philip Theodore

BRIEF-Aeterna Zentaris files claim against former CEO, former general counsel

* Aeterna Zentaris commences legal action against David Dodd and Philip Theodore

BRIEF-Aeterna Zentaris says ‍strategic review committee will be chaired by Carolyn Egbert, and includes Michael Cardiff​

* Aeterna Zentaris forms strategic review committee and appoints Michael Ward as CEO

BRIEF-NDA for Aeterna Zentaris' Macrilen granted PDUFA date

* NDA for Macrilen for the evaluation of growth hormone deficiency in adults granted December 30, 2017 PDUFA date

BRIEF-Aeterna Zentaris resubmits NDA for Macrilen for the evaluation of growth hormone deficiency in adults

* Aeterna Zentaris resubmits NDA for Macrilen™ for the evaluation of growth hormone deficiency in adults

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up